Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.74 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.74 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.74 |
| ▸ | GSK3B | P49841 | 1/20 | 0.74 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.74 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491252 | 0.89 | PDE10A (0.67) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2486948 | 0.88 | PDE10A (0.66) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL3317616 | 0.88 | PDE10A (0.69) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL13362191 | 0.87 | PDE10A (0.68) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL3317558 | 0.86 | PDE10A (0.73) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2487324 | 0.86 | PDE10A (0.57) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2492503 | 0.86 | PDE10A (0.57) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2494438 | 0.85 | PDE10A (0.67) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL3320350 | 0.85 | PDE10A (0.86) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2490725 | 0.85 | PDE10A (0.58) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | claimed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | claimed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | claimed |
| EP-2364306-A1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | claimed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2364306-A1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885CSNK1A1 2911/4885CSNK1D 2547/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885CSNK1A1 2911/4885CSNK1D 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.